- Home
- MCD vs ABBV Comparison
MCD vs ABBV Comparison
Compare MCD & ABBV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MCD | ABBV |
|---|---|---|
| Founded | 1940 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 204.6B | 451.5B |
| IPO Year | 1997 | 2012 |
Fundamental Metrics
Financial Performance| Metric | MCD | ABBV |
|---|---|---|
| Price | $248.61 | $264.77 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 29 | 18 |
| Target Price | ★ $344.17 | $253.71 |
| AVG Volume (30 Days) | ★ 4.0M | 2.5M |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | 2.56% | ★ 3.39% |
| EPS Growth | ★ 4.92 | N/A |
| EPS | ★ 6.10 | 2.42 |
| Revenue | $26,885,000,000.00 | ★ $61,160,000,000.00 |
| Revenue This Year | $7.65 | $11.87 |
| Revenue Next Year | $6.00 | $8.12 |
| P/E Ratio | ★ $40.86 | $109.15 |
| Revenue Growth | 3.72 | ★ 8.57 |
| 52 Week Low | $247.65 | $190.75 |
| 52 Week High | $341.75 | $267.47 |
Technical Indicators
Market Signals| Indicator | MCD | ABBV |
|---|---|---|
| Relative Strength Index (RSI) | 32.45 | 60.08 |
| Support Level | N/A | $243.68 |
| Resistance Level | $287.24 | N/A |
| Average True Range (ATR) | 3.60 | 5.02 |
| MACD | -0.67 | 0.55 |
| Stochastic Oscillator | 11.65 | 91.28 |
Price Performance
Historical ComparisonAbout MCD McDonald's Corporation
McDonald's is the world's largest restaurant brand, with nearly $139 billion in systemwide sales across more than 45,000 restaurants and over 100 markets. The quick-service chain built its early reputation on speed, consistency, and affordable hamburgers, and today its global menu spans burgers, chicken, breakfast, and beverages that have helped popularize American fast-food cuisine worldwide. The firm derives the bulk of its revenue from franchise royalties and rent (about 62%), with the remainder stemming from company-operated restaurants across three segments: the United States (39% of systemwide sales), international operated markets (35%), and international developmental/licensed markets (26%).
About ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.